The positive Final Appraisal Document (FAD) means Skyrizi (risankizumab) is recommended for severe psoriasis treatment in adults who have failed conventional systemic therapies.
The recommendation means that the NHS in England will make Skyrizi available from August, putting it into an already highly competitive field in psoriasis.
Skyrizi is a new entrant to the IL-23 inhibitor class, but has an advantage in being administered only every 12 weeks, compared to once every four weeks for established treatments.
NICE notes in its final appraisal that clinical trials shows Skyrizi is more effective than AbbVie’s now off-patent Humira (adalimumab) and J&J’s IL-12/IL-23 inhibitor Stelara (ustekinumab).
It adds that indirect comparisons suggest Skyrizi is likely to provide similar health benefits compared with J&J’s IL-23 inhibitor Tremfya (guselkumab) (which gained NICE recommendation a year ago) and better PASI (Psoriasis Area and Severity Index) response rates compared with many other biologicals…